Characterizing cathepsin activity and macrophage subtypes in excised human carotid plaques

Stroke

Volumn 47, Issue 4, 2016, Pages 1101-1108

  Abd Elrahman, Ihab ^a   Meir, Karen ^b   Kosuge, Hisanori ^d,e   Ben Nun, Yael ^a   Sadan, Tommy Weiss ^a   Rubinstein, Chen ^c   Samet, Yaacov ^c   McConnell, Michael V ^d   Blum, Galia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Department of Pathology ^*  (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Activity based probe; Atherosclerosis; Cathepsins; Macrophages; Optical imaging

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; FLUORESCENT DYE; GB 123; UNCLASSIFIED DRUG; CATHEPSIN;

ADULT; AGED; ARTICLE; ASYMPTOMATIC CAROTID ATHEROSCLEROSIS; ASYMPTOMATIC DISEASE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENZYME ACTIVITY; ENZYME ANALYSIS; EX VIVO STUDY; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SYMPTOMATIC CAROTID ATHEROSCLEROSIS; CAROTID ARTERY; CAROTID ARTERY DISEASES; METABOLISM; MIDDLE AGED; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CATHEPSINS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 84960194141     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011573     Document Type: Article

References (34)

1. Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C, et al. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci. 2012;1262:134-141. doi: 10.1111/j.1749-6632.2012.06600.x.
2. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med. 2008;5(suppl 2):S2-S10. doi: 10.1038/ncpcardio1247.
3. Hansson GK. Infammation, atherosclerosis, and coronary artery disease-reply. N Engl J Med. 2005;353:429-430.
4. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-infammatory properties. Cell Metab. 2007;6:137-143. doi: 10.1016/j.cmet.2007.06.010.
5. Broz P, Marsch S, Hunziker P. Targeting of vulnerable plaque macro-phages with polymer-based nanostructures. Trends Cardiovasc Med. 2007;17:190-196. doi: 10.1016/j.tcm.2007.05.002.
6. Reddy VY, Zhang QY, Weiss SJ. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci USA. 1995;92:3849-3853.
7. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macro-phages to promote cancer growth and invasion. Genes Dev. 2010;24:241-255. doi: 10.1101/gad.1874010.
8. Salpeter SJ, Pozniak Y, Merquiol E, Ben-Nun Y, Geiger T, Blum G. A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression. Oncogene. 2015;34:6066-6078. doi: 10.1038/onc.2015.51.
9. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359-1366. doi: 10.1161/01.ATV.0000134530.27208.41.
10. Li W, Yuan XM. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci. 2004;1030:427-433. doi: 10.1196/annals.1329.053.
11. Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766-2771.
12. Jormsjö S, Wuttge DM, Sirsjö A, Whatling C, Hamsten A, Stemme S, et al. Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-defcient mice. Am J Pathol. 2002;161:939-945. doi: 10.1016/S0002-9440(10)64254-X.
13. Samokhin AO, Wong A, Saftig P, Brömme D. Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-defcient mice. Atherosclerosis. 2008;200:58-68. doi: 10.1016/j.atherosclerosis.2007.12.047.
14. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 infammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361. doi: 10.1038/nature08938.
15. Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, et al. Defciency of cathepsin S reduces atherosclerosis in LDL receptor-def-cient mice. J Clin Invest. 2003;111:897-906. doi: 10.1172/JCI14915.
16. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fuores-cently quenched activity-based probes. Nat Chem Biol. 2007;3:668-677. doi: 10.1038/nchembio.2007.26.
17. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, et al. Dynamic imaging of protease activity with fuorescently quenched activity-based probes. Nat Chem Biol. 2005;1:203-209. doi: 10.1038/nchembio728.
18. Li W, Kornmark L, Jonasson L, Forssell C, Yuan XM. Cathepsin L is sig-nifcantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis. 2009;202:92-102. doi: 10.1016/j. atherosclerosis.2008.03.027.
19. Kitamoto S, Sukhova GK, Sun J, Yang M, Libby P, Love V, et al. Cathepsin L defciency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation. 2007;115:2065-2075. doi: 10.1161/CIRCULATIONAHA.107.688523.
20. Liu J, Sukhova GK, Yang JT, Sun J, Ma L, Ren A, et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis. 2006;184:302-311. doi: 10.1016/j.atherosclerosis.2005.05.012.
21. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, et al. Detecting and assessing macro-phages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA. 2007;104:961-966. doi: 10.1073/pnas.0606281104.
22. Hyafl F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13:636-641. doi: 10.1038/nm1571.
23. Trivedi RA, Mallawarachi C, U-King-Im JM, Graves MJ, Horsley J, Goddard MJ, et al. Identifying infamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26:1601-1606. doi: 10.1161/01. ATV.0000222920.59760.df.
24. McCarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranos-tic nanoparticle for biomedical applications. Small. 2006;2:983-987. doi: 10.1002/smll.200600139.
25. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, et al. Noninvasive vascular cell adhesion molecule-1 imaging iden-tifes infammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504-1511. doi: 10.1161/CIRCULATIONAHA.106.646380.
26. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, et al. RGD peptide functionalized and reconstituted high-density lipopro-tein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 2010;24:1689-1699. doi: 10.1096/fj.09-139865.
27. Laitinen I, Saraste A, Weidl E, Poethko T, Weber AW, Nekolla SG, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular infammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2:331-338. doi: 10.1161/CIRCIMAGING.108.846865.
28. Michalska M, Machtoub L, Manthey HD, Bauer E, Herold V, Krohne G, et al. Visualization of vascular infammation in the atherosclerotic mouse by ultrasmall superparamagnetic iron oxide vascular cell adhesion molecule-1-specifc nanoparticles. Arterioscler Thromb Vasc Biol. 2012;32:2350-2357. doi: 10.1161/ATVBAHA.112.255224.
29. Ouimet T, Lancelot E, Hyafl F, Rienzo M, Deux F, Lemaître M, et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm. 2012;9:850-861. doi: 10.1021/mp2003863.
30. Cho KY, Miyoshi H, Kuroda S, Yasuda H, Kamiyama K, Nakagawara J, et al. The phenotype of infltrating macrophages influences arterioscle-rotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis. 2013;22:910-918. doi: 10.1016/j.jstrokecerebrovasdis.2012.11.020.
31. Calfon MA, Rosenthal A, Mallas G, Mauskapf A, Nudelman RN, Ntziachristos V, et al. In vivo near infrared fuorescence (nirf) intravas-cular molecular imaging of infammatory plaque, a multimodal approach to imaging of atherosclerosis. Journal of visualized experiments: JoVE. 2011;54:e2257
32. Calfon MA, Vinegoni C, Ntziachristos V, Jaffer FA. Intravascular near-infrared fuorescence molecular imaging of atherosclerosis: toward coronary arterial visualization of biologically high-risk plaques. J Biomed Opt. 2010;15:011107. doi: 10.1117/1.3280282.
33. Blum G, Weimer RM, Edgington LE, Adams W, Bogyo M. Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One. 2009;4:e6374. doi: 10.1371/journal.pone.0006374.
34. 64Cu-labeled activity-based probe. PLoS One. 2011;6:e28029. doi: 10.1371/journal.pone.0028029.